cell therapies

News

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.

News

FDA advisors vote no to Capricor's DMD therapy

FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.

News

ASCO26: In vivo CAR-Ts in the spotlight

Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.

Oncology

CAR-NK cell therapies for solid tumours: Closing the gap bet...

CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.

R&D

Biotech’s biggest challenge isn’t scientific, but political ...

We speak to James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy & grandson of FDR

News